This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.62% per year. These returns cover a period from January 1, 1988 through June 2, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Image: Bigstock
Bear of the Day: NeuroPace (NPCE)
NeuroPace (NPCE - Free Report) is a $200 million commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from epilepsy. NeuroPace Inc. is based in Mountain View, CA.
The company's patented RNS® System is the only FDA-approved epilepsy device that delivers personalized treatment by responding to abnormal brain activity and provides EEG data that can help improve patient care.
The RNS System is a treatment for adults with drug-resistant focal epilepsy. The NeuroPace website describes the benefits of their platform with these three key benefits...
The RNS System can help patients achieve significant seizure reduction and quality of life improvements.
Data from the RNS System provides unprecedented visibility into seizure trends and triggers that can help physicians optimize patient treatment plans.
The RNS System responds to a patient’s unique seizure fingerprint -- so patients get the treatment they need, when they need it.
A Longer Path to EPS Growth
The reason that NPCE is in the cellar of the Zacks Rank is due to recent disappointments on their quarterly earnings reports.
After their most recent report, the three Wall Street analysts providing earnings model coverage revised their consensus EPS projection down 52% for this year from a loss of $1.29 to a loss of $1.96.
And the Zacks EPS consensus for 2023 was dropped 51% from a loss of $1.04 to a loss of $1.57.
The good news is that for now, the 2023 consensus projection for $56.7 million in revenue, representing 22.8% growth, is still intact. This means the stock is trading under four times forward sales estimates.
NeuroPace is an exciting company with what appears to be an innovative solution to treating epilepsy. As soon as earnings estimates stop going down and stabilize, it could be a welcome addition to a portfolio seeking small-cap medical device growth.
The Zacks Rank will let you know.